Combined chondroprotectors in the treatment of osteoartritis


  • L.V. Derymedvid National University of Pharmacy, Kharkiv, Ukraine
  • V.P. Vereitinova National University of Pharmacy, Kharkiv, Ukraine



osteoarthritis, diclofenac potassium, gluco­samine sulfate, chondroitin sulfate


Osteoarthritis is a polyethiologic disease, the emergence and development of which is determined by a number of genetic, mechanical, hormonal and metabolic factors that violate the stability of hyaline cartilage and its physiological regeneration under the influence of loading. A characteristic feature is the destruction of articular cartilage and bone adjacent to it, pain, synovitis, violation or restriction of functional activity of the joints. Osteoarthritis pharmacotherapy includes analgesics, non-steroidal anti-inflammatory drugs and symptomatic slow acting drugs that modify cartilage structure (glucosamine, chondroitin, etc.).


Download data is not yet available.


Badokin VV. Multifactoriness of the mechanisms of action of nonsteroidal anti-inflammatory drugs in osteoarthrosis. Sovremennaya Revmatologiya. 2009;(4):81-87.

Burov NY. The use of nonsteroidal anti-inflammatory drugs in anesthesiology and resuscitation. RMJ. 2007;15(29):2206-2210.

Golovach IYu. Strategic decisions for safe and potential long-term therapy of osteoarthritis with NSAIDs. Travma. 2017;18(4):27-34. doi: 10.22141/1608-1706.4.18.2017.109341.

Golovach IYu. Osteoarthritis: the fundamental and applied aspects of the disease`s etiopathogenesis. Nothing stands still. Ukrai'ns'kyj revmatologichnyj zhurnal. 2014;(2):4-11.

Golovach IYu. Metabolic phenotype of osteoarthritis: double role of obesity. Travma. 2017;8(5):87-94. doi: 10.22141/1608-1706.5.18.2017.114124.

Davidov OS. The peripheral and central mechanisms of transition of acute to chronic pain and the possible role of cyclooxygenase-2 inhibition in the prevention of pain syndrome chronization. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2016;8(2):10-16. doi:10.14412/2074-2711-2016-2-10-16.

Denisov LN. Place of diclofenac in the therapy of pain syndromes. RMJ. 2009;17(21):1434-1436.

Derymedvid LV. The role of drugs that affect the metabolism of cartilage, in the treatment of osteoarthritis. Simejna medycyna. 2016;(64):39-42.

Zupanets IA. The phenomenon of synergism in modern chondroprotectors. Novosti meditsiny i farmatsii. 2009;(289):1-2.

Zupanets IA, Andreeva YeА. To the characteristic of gastrotoxic action of non-steroidal anti-inflammatory drugs - nonselective, selective and specific inhibitors of COX-2 (experimental study). Modern Gastroenterology. 2005;(22):39-43.

Kozachok NN, Seliuk MN. The leader of the XXI century in the treatment of pain syndrome Ukrai'ns'kyj medychnyj chasopys. 2010;(77):55-58.

Komissarov IV, Abramets II. Moduliatsiia effektivnosti mezhneironnykh sviazei bioreguliatorami i farmakologicheskimi sredstvami [Modulation of the efficacy of neuronal connections by bioregulators and pharmacological agents]. Kyiv: Naukova dumka; 1994. 190 p.

Alekseeva LI, Sharapova EP, Taskina EA, et al. Multicenter double-blind randomized placebo-controlled trial of the symptom-and structure-modifying effect of alflutop in patients with knee osteoarthrosis. communication 1. Evaluation of the symptom-modifying effect of the drug. Nauchno-prakticheskaya revmatologiya. 2013;51(5):532-538. doi: 10.14412/1995-4484-2013-1545.

Nasonov YL. Nonsteroidal anti-inflammatory drugs: new aspects of use in rheumatology and cardiology. RMJ. 2003;23(23):1280.

Popova LD. Effect of kynurenic acid on the excitatory and inhibitory mediators in rats with different levels of convulsive readiness. Ukr Biochem J. 2006;78(5):120-126.

Iadlovskyi OE. The role of vaniloid receptor TRPV1 in antynociceptive action of diclofenac Farmakologija ta likars'ka toksykologija. 2012;(1):60-64.

Dale WE, Dung Y, Amiridze M, Brown OP. Evidence that kynurenine pathway metabolites mediate hyperbaric – reduced convulsions. Toxicol Lett. 2000 Sep 30;117(1-2):37-43. PMID: 11033231.

David-Raoudi M, Mendichi R, Pujol JP. For intra–articular delivery of chondroitin sulfate. Glycobiology. 2009 Aug;19(8):813-5. doi: 10.1093/glycob/cwp069.

Edwards SR, Mather LE, Lin Y, Power I, Cousins MJ. Glutamate and kynurenate in the rat central nervous system following treatments with tail ischaemia or diclofenac. J Pharm Pharmacol. 2000 Jan;52(1):59-66. PMID: 10716604.

Maccarrone M, Bab I, Bíró T, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015 May;36(5):277-296. doi: 10.1016/j. tips.2015.02.008.

Graven-Nielsen T, Wodehouse T, Langford RM, Arendt-Nielsen L, Kidd BL. Normalization of widespread hyperesthesia and facilitated spatial summation of deep-tissue pain in knee osteoarthritis patients after knee replacement. Arthritis Rheum. 2012 Sep;64(9):2907-16. doi: 10.1002/art.34466.

Hochberg MC, Zhan M, Langenberg P. The rate of decline of joint space width in patients with osteoarthritis of the knee: a systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulphate. Curr Med Res Opin. 2008 Nov;24(11):3029-35. doi: 10.1185/03007990802434932 .

Hochberg MC. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis an updated meta-analysis of randomized placebo-controlled trils of 2-year duration. Osteoarthritis Cartilage. 2010 Jun;18 Suppl 1:S28-31. doi: 10.1016/j.joca.2010.02.016.

Kelly JC. For Arthritis Pain: Diclofenac Best, Acetaminophen Worst. Available from: Accessed: March 17, 2016.

Joel K, Lamdani-Itkin H, Sokolovsky M. The glycine site of the N-methyl-D-aspartate receptor channel: differences between the binding of НA-966 and of 7-chloro- kynurenic acid. J Neurochem. 1990 May;54(5):1576-83. PMID: 1691278.

Malfait AM. Osteoarthritis year in review 2015: biology. Osteoarthritis Cartilage. 2016 Jan;24(1):21-6. doi: 10.1016/j.joca.2015.09.010.



How to Cite

Derymedvid, L., & Vereitinova, V. (2021). Combined chondroprotectors in the treatment of osteoartritis. PAIN, JOINTS, SPINE, 8(1), 31–36.



Practical Medicine